The Cannabis Alliance

Convened experts had no definitive answer for distinguishing impairing THCs or other cannabinoids, but agreed research was needed to create a legally defensible standard.

Legislative leaders of cannabis policy committees talked about a few successes in 2022, and the more numerous failures around medical cannabis, equity, and cannabinoid regulation bills.

After DOH representatives provided a brief background, two patients, a medical consultant, and a consultant trainer offered feedback on proposed changes to consultant certification rules.

WSLCB staff would accept feedback on the upcoming social equity retail licensure window and the Cannabis Alliance planned to host leading legislators to discuss what happened in 2022.

The caucus meeting touched on existing rulemaking; a proposal to label cannabis vapor cartridges; the highs and lows of the legislative session; and a newly appointed board member.

A last-minute hearing on a repackaged bill to regulate synthesized cannabinoids revealed shared public health concerns but testimony otherwise remained just as sharply divided.

Testimony on a bill to exempt registered medical cannabis patients from the excise tax on DOH compliant products was supportive and elicited several questions from lawmakers.

The work group welcomed new members, discussed previously approved recommendations, and hosted an open discussion on potential new license types for equity applicants.

A bill to grant all medical cannabis patients protection from arrest received almost entirely positive testimony, along with complaints about homegrowing and cannabis scheduling policy.

After more than three years, rulemaking on pesticide testing still elicited criticism from many producers and processors, though a few stakeholders suggested enacting and moving on.